Unicentric Retrospective Analysis of a Cohort of 602 Young Adult and Adolescent Patients (AJA), Aged 15 to 30 Years, With Haematological Malignancies, and Managed Between 2000 and 2016

Study Overview
=================
Brief Summary
-----------------
Unicentric retrospective analysis of a cohort of 602 young adult and adolescent patients, aged 15 to 30 years, with haematological malignancies, and managed between 2000 and 2016

Detailed Description
-----------------
The therapeutic results (response and survival) of young adult and adolescent patients with hematological malignancies are generally lower than those usually observed in adults over the age of 30, with equivalent treatment, particularly in lymphomatous pathology.The overall analysis of this large cohort of patients in its entirety, then by age groups (15-17 years, 18-25 years, 26-30 years) and pathology aims to describe the future of patients and patients. compare them to the results of the literature observed in this age group, and according to the therapeutic regimens administered (pediatric regimen or adult regimen).

Official Title
-----------------
Unicentric Retrospective Analysis of a Cohort of 602 Young Adult and Adolescent Patients (AJA), Aged 15 to 30 Years, With Haematological Malignancies, and Managed Between 2000 and 2016

Conditions
-----------------
Malignant Haemopathies, Acute Leukemia, Non-hodgkin Lymphoma, Hodgkin Lymphoma

Intervention / Treatment
-----------------
* Drug: administered therapeutic regimens


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Malignant hemopathies (acute leukemia, non-Hodgkin's lymphoma, Hodgkin's lymphoma) in primary care between 2000 and 2016. Exclusion Criteria: Not applicable

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 15-17 years old<br>15-17 years old | Drug: administered therapeutic regimens<br>* administered therapeutic regimens<br>|
| 18-25 years old<br>18-25 years old | Drug: administered therapeutic regimens<br>* administered therapeutic regimens<br>|
| 26-30 years old<br>26-30 years old | Drug: administered therapeutic regimens<br>* administered therapeutic regimens<br>|
| acute leukemia<br>acute leukemia | Drug: administered therapeutic regimens<br>* administered therapeutic regimens<br>|
| non-Hodgkin's lymphoma<br>non-Hodgkin's lymphoma | Drug: administered therapeutic regimens<br>* administered therapeutic regimens<br>|
| Hodgkin lymphoma<br>Hodgkin lymphoma | Drug: administered therapeutic regimens<br>* administered therapeutic regimens<br>|
| pediatric therapeutic regimen administered<br>pediatric therapeutic regimen administered | Drug: administered therapeutic regimens<br>* administered therapeutic regimens<br>|
| adult therapeutic regimen administered<br>adult therapeutic regimen administered | Drug: administered therapeutic regimens<br>* administered therapeutic regimens<br>|
| patients included in clinical trials<br>patients included in clinical trials | Drug: administered therapeutic regimens<br>* administered therapeutic regimens<br>|
| patients not included in clinical trials<br>patients not included in clinical trials | Drug: administered therapeutic regimens<br>* administered therapeutic regimens<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Global Survival | delay between the date of diagnosis and the date of the latest news | 15 years | 
| Survival without event | delay between the date of diagnosis and an event (relapse, death, lost of follow-up) | 15 years | 
| Progression-free survival | defined as the delay between the date of diagnosis and the date of relapse or death. | 15 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Epidemiological distribution by pathology compared to the adult population over 30 years | Epidemiological distribution by pathology compared to the adult population over 30 years | 1 day | 
| Descriptive analysis of the characteristics of the disease at diagnosis by pathology | Descriptive analysis of the characteristics of the disease at diagnosis by pathology | 15 years | 
| Descriptive analysis of treatments by pathology | Descriptive analysis of treatments by pathology | 15 years | 
| Overall survival (OS) of patients included in clinical trials compared to patients not included for the overall cohort and pathology | Overall survival (OS) of patients included in clinical trials compared to patients not included for the overall cohort and pathology | 15 years | 
| Event-free survival (EFS) of patients included in clinical trials compared to patients not included for the overall cohort and pathology | Event-free survival (EFS) of patients included in clinical trials compared to patients not included for the overall cohort and pathology | 15 years | 
| Progression-free survival (PFS) of patients included in clinical trials compared to patients not included for the overall cohort and pathology | Progression-free survival (PFS) of patients included in clinical trials compared to patients not included for the overall cohort and pathology | 15 years | 
| Long-term toxicity analysis (second cancers, fertility) for the global cohort and pathology. | Long-term toxicity analysis (second cancers, fertility) for the global cohort and pathology. | 15 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Malignant haemopathies, Acute Leukemia, Non-hodgkin Lymphoma, Hodgkin Lymphoma, Young adults, Adolescent